NanoViricides President Dr. Diwan to Present at the Wall Street Analyst Forum Today, June 19th, in New York City
June 19 2014 - 8:30AM
Business Wire
NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports
that its President, Dr. Anil Diwan, will be presenting at the Wall
Street Analyst Forum’s 25th Annual Institutional Investor
Conference today at 11:20am Eastern Time at the University Club in
New York City. The event is being webcast. To participate, the
registration link is
http://www.visualwebcaster.com/event.asp?id=99581. Investors
interested in attending the presentation in person may register at:
www.analyst-conference.com/investor-registration.
Dr. Diwan will provide an update on the Company’s drug programs,
and the cGMP clinical drug manufacturing facility.
The construction phase of the total renovation at the Shelton,
CT, site is almost complete. Specific modifications for processing
equipment are now in progress. Facility Validation work has
started. The fully customizable manufacturing facility will enable
cGMP manufacture of all of our nanoviricides® drug candidates in
kilogram scale, sufficient for pre-IND and human clinical
studies.
The Company recently reported that it was in the preliminary
list of additions to certain Russell Indexes including Russell
2000, Russell 3000, and the Russell Small Cap.
The Company’s first drug candidate is injectable FluCide™ for
all influenzas in hospitalized patients. The market size for an
effective influenza drug for treating severely ill hospitalized
patients has been estimated in the billions of dollars, worldwide,
depending upon the therapeutic value and cost savings. Currently,
there is no effective therapeutic available for this indication.
The Company believes that it could supply a substantial portion of
the demand for this drug from its new small scale cGMP clinical
drug facility. This drug is currently in IND-enabling studies.
This drug candidate has demonstrated an unparalleled 1,000-fold
reduction in lung viral load in a lethal animal model study. In the
same study, the current standard of care, oseltamivir, (Tamiflu®,
Roche) exhibited only a 2-fold reduction in lung viral load at the
same time point. The Company intends to begin the safety/toxicology
studies of this Injectable FluCide™ drug candidate as soon as
feasible, and is producing sufficient drug substance for these
studies at its existing facility.
This broad-spectrum FluCide drug is expected to work against
most, if not all, forms of influenza virus, including epidemic,
pandemic (e.g. H1N1/2009), high path influenzas such as H3N2, H7N9,
and “bird flu” such as H5N1.
The total market size addressed by the Company’s current drug
programs is estimated at about $50 billion. In addition to
Injectable FluCide, the Company is working on five more
commercially important drug candidates, namely: DengueCide™,
HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a
broad-spectrum antiviral drug for viral diseases of the external
eye. All of our programs are for therapeutics to treat viral
infections. Our drugs are expected to be useful as prophylactics as
well. DengueCide has recently received orphan drug designation by
the US FDA as well as the European EMA.
NanoViricides recently received an important international
award, the “IAIR Award 2014 for Leadership in Nanomedicines in the
North American Sector”.
The Company currently has approximately $36 million cash-in-hand
and cash-like-instruments. These funds are estimated to be
sufficient for taking at least one of our drug candidates through
initial human clinical trials, and possibly take another drug
candidate into human clinical trials.
About The Wall Street Analyst Forum Conferences:Our June 2014
investor conference is our 25th Annual Investor Conference. We have
been a leading sponsor of institutional investor conferences in New
York City, Boston and London since 1989. Over 2200 corporations,
from General Electric, Pfizer, Mattel to Nokia, have presented and
institutional investors from 2000 money management firms have
attended. In 1998 we received extensive coverage in the financial
press for conducting the first live webcast of individual corporate
meetings from an investor conference.
About NanoViricides:NanoViricides,
Inc. (www.nanoviricides.com)
is a development stage company that is creating special purpose
nanomaterials for viral therapy. The Company's novel nanoviricide®
class of drug candidates are designed to specifically attack
enveloped virus particles and to dismantle them. The Company is
developing drugs against a number of viral diseases including H1N1
swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital
Herpes, viral diseases of the eye including EKC and herpes
keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus,
among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon, 310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jul 2023 to Jul 2024